Department of Dermatology, Zhejiang Provincial Dermatology Hospital, Huzhou, Zhejiang, China.
PLoS One. 2024 Aug 28;19(8):e0308986. doi: 10.1371/journal.pone.0308986. eCollection 2024.
It still needs to be determined if platelet-rich plasma (PRP) has any added advantage over Minoxidil in treating androgenetic alopecia. We reviewed randomized controlled trials (RCTs) comparing scalp injections of PRP plus Minoxidil vs Minoxidil alone for managing androgenetic alopecia.
All RCTs published on Embase, Cochrane Library, and PubMed comparing PRP plus Minoxidil vs. Minoxidil alone were eligible. The literature search was completed on 5 March 2024. The review was registered on PROSPERO (CRD42024509826).
Of five included RCTs, three had a high risk of bias, while one had some concerns. A systematic review of the studies showed that all trials reported better outcomes with PRP plus Minoxidil than with Minoxidil alone. Meta-analysis showed that hair density at one month (MD: 11.07 95% CI: 1.20, 20.94 I2 = 0%), three months (MD: 21.81 95% CI: 10.64, 33.00 I2 = 57%) and 5/6 months (MD: 17.80 95% CI: 7.91, 27.69 I2 = 80%) of follow-up was significantly better in the PRP plus Minoxidil vs the Minoxidil alone group. Meta-analysis of adverse events showed that the risk of adverse events was comparable in both groups (OR: 0.55 95% CI: 0.22, 1.36 I2 = 0%). The certainty of evidence on the GRADE assessment was "low to very low."
Very low-quality evidence shows that the addition of injectable PRP to topical Minoxidil may improve outcomes in patients with androgenetic alopecia. The addition of PRP was found to improve hair density and patient satisfaction significantly. However, the small number of studies with a high risk of bias and heterogeneity in PRP preparation methods are significant limitations of current evidence. Further studies with larger sample sizes and uniform PRP preparation protocols are needed.
仍需确定富血小板血浆(PRP)在治疗雄激素性脱发方面是否比米诺地尔有额外优势。我们回顾了比较头皮注射 PRP 加米诺地尔与单独使用米诺地尔治疗雄激素性脱发的随机对照试验(RCT)。
符合条件的是在 Embase、Cochrane 图书馆和 PubMed 上发表的比较 PRP 加米诺地尔与单独使用米诺地尔的所有 RCT。文献检索于 2024 年 3 月 5 日完成。该综述在 PROSPERO(CRD42024509826)上进行了注册。
纳入的 5 项 RCT 中有 3 项存在高偏倚风险,而 1 项存在一些担忧。对研究的系统评价表明,所有试验均报告 PRP 加米诺地尔治疗的结果优于单独使用米诺地尔。Meta 分析显示,1 个月时的毛发密度(MD:11.07,95%CI:1.20,20.94,I2 = 0%)、3 个月(MD:21.81,95%CI:10.64,33.00,I2 = 57%)和 5/6 个月(MD:17.80,95%CI:7.91,27.69,I2 = 80%)时的毛发密度明显优于米诺地尔组。对不良反应的 Meta 分析显示,两组不良反应的风险相当(OR:0.55,95%CI:0.22,1.36,I2 = 0%)。基于 GRADE 评估的证据确定性为“低到极低”。
低质量证据表明,在局部用米诺地尔中添加可注射的 PRP 可能改善雄激素性脱发患者的结局。添加 PRP 可显著改善毛发密度和患者满意度。然而,由于研究存在高偏倚风险以及 PRP 制备方法的异质性,目前的证据存在显著局限性。需要进一步开展样本量更大且 PRP 制备方案统一的研究。